Six Diets Tied to Lower Risk of Cognitive Decline

 None of them have any objective specifics(NO protocol!) so you can be sure you're following them properly. In my opinion, pretty much useless other than whitewashing your doctor's incompetence in not knowing anything specific to get you recovered!

Six Diets Tied to Lower Risk of Cognitive Decline

One midlife plan showed the best brain health measures later in life

Key Takeaways

• Six dietary patterns were associated with a lower relative risk of subjective cognitive decline.
• The DASH diet had the lowest subjective decline risk and the strongest relationship with objective cognitive function.
• Associations were most pronounced when the DASH diet was followed at ages 45 to 54.

Healthcare professionals who followed six healthy eating patterns in midlife had less risk of long-term cognitive decline and better cognitive function, a large prospective study showed.

Among nearly 160,000 health professionals with a mean age of 44, those who followed these six dietary patterns had a lower relative risk (RR) of subjective cognitive decline, comparing the top and bottom 10% of adherence:

• Dietary Approaches to Stop Hypertension (DASH): RR 0.59, 95% CI 0.57-0.62
• Healthful Plant-Based Diet Index: RR 0.76, 95% CI 0.65-0.85
• Reversed Empirical Dietary Indices for Hyperinsulinemia: RR 0.76, 95% CI 0.73-0.80
• Planetary Health Diet Index: RR 0.80, 95% CI 0.75-0.86
• Alternate Healthy Eating Index 2010 (AHEI-2010): RR 0.84, 95% CI 0.80-0.89
• Reversed Empirical Dietary Indices for Inflammatory Pattern: RR 0.89, 95% CI 0.85-0.93

The DASH diet had not only the lowest subjective cognitive decline risk, but the strongest relationship with higher objectively measured global cognition with a mean z score difference of 0.05 (95% CI 0.02-0.09), reported Kjetil Bjornevik, MD, PhD, of the Harvard T.H. Chan School of Public Health in Boston, and co-authors in JAMA Neurology.

Associations were most pronounced when the DASH diet was followed in midlife, at ages 45 to 54.

Diet is one of several modifiable risk factors that may help reduce dementia risk, but evidence about what type of diet matters most for cognitive health is inconsistent, Bjornevik noted.

"What was encouraging about our findings was the consistency across different types of diet, which suggests that there is not just one right approach and that different dietary strategies may have beneficial effects on cognitive health," Bjornevik told MedPage Today.

"We selected these six patterns to cover a broad range of dietary approaches," he pointed out.

"They include general diet quality indices like the AHEI-2010, the DASH diet which targets blood pressure, plant-based and sustainability-oriented patterns, and data-driven patterns that capture dietary influences on insulin and inflammatory pathways," he said. "This allowed us to compare how different dietary strategies relate to cognitive health within the same populations."

The researchers followed professionals in three ongoing cohorts: the Nurses' Health Study (NHS), the Health Professionals Follow-Up Study (HPFS), and the NHSII. Earlier findings from the NHS and the HPFS reported that higher intake of red and processed meat was associated with worse cognitive outcomes over 43 years of follow-up.

Research in other cohorts has linked ultraprocessed foods with cognitive decline and has shown that cognitive risks drop when diets include more minimally processed food. Inflammatory foods like saturated fats have been tied to increased dementia risk in the Framingham Heart Offspring cohort.

The MIND diet -- a hybrid of the Mediterranean and the DASH diets -- has been linked with higher brain volumes among U.K. Biobank participants. Most recently, researchers reported that a Mediterranean diet was associated with less dementia risk and slower cognitive decline in people who carried the APOE4 Alzheimer's risk gene.

The DASH dietary plan, which had the best outcomes in the current study, promotes eating vegetables, fruits, whole grains, fat-free or low-fat dairy products, fish, poultry, beans, nuts, and vegetable oils. It recommends limiting foods high in saturated fat, sugary beverages and sweets, and sodium intake.

Bjornevik and colleagues followed 62,412 women in the NHS from 1986-2014; 27,787 men in the HPFS from 1986-2012; and 69,148 women in the NHSII from 1991-2017. Most participants in the study were female (82.6%) and white (96.2%).

Self-reported subjective cognitive decline was assessed with seven questions about perceived cognitive changes in memory, executive function, attention, and visuospatial skills. Cognitive function was objectively measured only in the NHS cohort with telephone-based cognitive tests among nurses ages 70 and older, followed by three rounds of biennial follow-up assessments.

Diet was evaluated with food frequency questionnaires every 4 years. Because early cognitive symptoms can affect eating patterns, the researchers stopped updating diet scores 6 years before subjective cognitive decline assessments and 5 years before objective testing.

Overall, green-leafy, yellow, and other vegetables were significantly associated with better cognition in the study. Fried (but not nonfried) potatoes were tied to a higher risk of subjective cognitive decline and worse objective cognitive performance. Fish intake correlated with better cognitive function, and red meat, processed meat, and eggs were linked with worse cognitive outcomes.

The DASH diet targets blood pressure, the researchers observed. "Although direct evidence for the mediation role of hypertension in diet-cognition pathways remains limited, our findings aligned with prior literature on the cognitive benefits of blood pressure control and cognitive health," they noted.

The study had several limitations, the researchers acknowledged. Subjective cognitive decline may be influenced by individual differences in health awareness or reporting tendencies, they noted. Unmeasured variables also may have influenced results.

Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Connect:

Disclosures

This analysis was supported by grants from the Zhejiang University Global Partnership Fund and the Alzheimer's Association.

The Nurses' Health Study (NHS), the Health Professionals Follow-Up Study, and the NHSII cohorts were supported by the NIH.

Bjornevik had no disclosures. Co-authors received grants from the NIH.

Primary Source

JAMA Neurology

Source Reference: Chen H, et al "Dietary patterns and indicators of cognitive function" JAMA Neurol 2026; DOI: 10.1001/jamaneurol.2026.0062.

The Age‑Well Project - WALKING POLES: WHY WE ALL NEED A PAIR

This would require your doctor have EXACT STROKE REHAB PROTOCOLS to recover your arm and hand. I have zero left arm use to even attempt this.

  The Age‑Well Project - WALKING POLES: WHY WE ALL NEED A PAIR

DASH diet linked to lower risk of cognitive decline

 You'll have to ask your competent? doctor for the EXACT SPECIFIC VERSION OF THIS! You wouldn't want to do it wrong, would you? No excuses are allowed.

DASH diet linked to lower risk of cognitive decline

In a large prospective analysis of 159,347 adults from the Nurses’ Health Study, Nurses’ Health Study II, and Health Professionals Follow-Up Study, greater adherence to 6 established healthy dietary patterns was consistently associated with lower risk of subjective cognitive decline, with the Dietary Approaches to Stop Hypertension (DASH) diet showing the strongest effect and the most robust link to better objectively measured global cognition.

In the study, published in JAMA Neurology, individuals in the highest versus lowest decile of DASH adherence had 41% lower odds of subjective cognitive decline, reinforcing dietary quality as a modifiable strategy clinicians can emphasise to support long-term cognitive health.

“These findings support the importance of healthy eating as part of midlife brain-health strategies and motivate pragmatic and implementation research to translate these findings into scalable programs,” wrote Hui Chen, PhD, Harvard School of Public Health, Boston, Massachusetts, and colleagues.

The researchers assessed 6 dietary pattern scores, including the Alternate Healthy Eating Index 2010, the DASH diet score, the Healthful Plant-Based Diet Index, the Planetary Health Diet Index, and the reversed empirical dietary indices for hyperinsulinemia and inflammatory pattern.

Dietary intake was repeatedly assessed using validated food frequency questionnaires, and cognitive outcomes were evaluated through self-reported measures of perceived decline and, in a subset, telephone-based cognitive testing, with analyses conducted across several decades of follow-up.

Higher adherence to all 6 dietary patterns was associated with significantly lower risk of subjective cognitive decline, with the DASH diet demonstrating the strongest association (risk ratio = 0.59 comparing highest vs lowest adherence) and the most robust link to better global cognitive scores.

Diets rich in vegetables and fish and lower in red and processed meats were particularly associated with favorable outcomes, underscoring the role of cardiometabolic-friendly dietary patterns as a potentially modifiable strategy to preserve long-term cognitive health.

While subgroup analyses hinted that lifestyle factors such as physical activity might modify these associations, the study was not powered to formally test interactions, underscoring the need for larger studies and long-term clinical trials. 

Reference: https://jamanetwork.com/journals/jamaneurology/fullarticle/2845466

SOURCE: JAMA Neurology

Imaging study reveals LATE as common, overlapping cause of cognitive decline

 With your already high risk of dementia post stroke, will your doctor guarantee that this won't occur to you?

With your risk of dementia, you need this prevented.

Parkinson’s Disease May Have Link to Stroke March 2017 

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018

The latest here:

Imaging study reveals LATE as common, overlapping cause of cognitive decline

In a retrospective analysis of 944 patients undergoing 18F-fluoro-deoxy-glucose positron emission tomography( [¹⁸F] FDG PET) imaging for cognitive decline, 13% showed imaging patterns consistent with probable limbic-predominant age-related TDP-43 encephalopathy (LATE) -- including 10.6% with mixed LATE and Alzheimer disease (AD) -- while 23.7% were classified as probable AD alone, underscoring LATE as a common and often overlapping contributor to dementia.

Using autopsy-confirmed imaging templates from the Alzheimer’s Disease Neuroimaging Initiative, the study identified distinct regional metabolic and MRI atrophy signatures, particularly involving the medial temporal lobe, entorhinal cortex, and amygdala, and demonstrated synergistic, predominantly left-sided brain involvement in mixed LATE+AD cases, highlighting the growing importance of biomarker-driven differentiation for accurate diagnosis and targeted management in aging populations.

The findings were published in The Journal of Nuclear Medicine.

“The distinction in the causes of these types of dementia is critical, especially in the era of anti-amyloid therapies,” said Satoshi Minoshima, MD, University of Utah, Salt Lake City, Utah. “Because LATE has a different underlying pathology and a seemingly different prognosis, it cannot be diagnosed or treated in the same way as Alzheimer's disease.”

Currently, LATE can only be definitively distinguished from Alzheimer's disease through postmortem neuropathology. Because no clinically approved biomarker is available to identify LATE, physicians rely on a diagnostic framework that focuses on PET, MRI, and clinical assessment.

“This has resulted in a significant gap in the diagnosis and management of LATE,” said Dr. Minoshima. “Our study aimed to introduce a quantitative diagnostic framework using commonly available imaging tests to identify LATE, which can be applied in clinics with limited access to advanced biomarkers.”

The researchers retrospectively analysed 944 patients referred to a tertiary cognitive disorders clinic to investigate biomarkers of probable LATE and AD. Autopsy-confirmed PET templates from the Alzheimer’s Disease Neuroimaging Initiative and University of Utah datasets were used to create 3-dimensional stereotactic surface projection maps, allowing objective classification of patients into probable LATE, probable LATE+AD, and probable AD. MRI volumetry was applied to assess regional brain atrophy.

The study found that 13% of patients exhibited probable LATE (2.4% pure LATE, 10.6% LATE+AD), while 23.7% showed probable AD alone. Pure LATE cases had pronounced medial temporal lobe atrophy, whereas mixed LATE+AD cases showed vulnerability in the orbitofrontal gyrus and lateral temporal lobe. The entorhinal cortex and amygdala were key regions distinguishing mixed from pure pathologies. Notably, LATE+AD cases demonstrated synergistic left-dominant metabolic and structural changes.

“The imaging patterns identified on PET and MRI in this study provide clinicians with a practical tool to detect potential LATE pathology in patients with cognitive impairment and to inform clinical management and future investigations of LATE,” said Dr. Minoshima. “These efforts will ultimately advance precision diagnostics and treatment stratification in molecular imaging and nuclear medicine.”

Reference: https://jnm.snmjournals.org/content/early/2026/01/22/jnumed.125.270614

SOURCE: Society of Nuclear Medicine and Molecular Imaging

Two Days of Oatmeal May Lower Bad Cholesterol by 10 Percent, Study Finds

 Didn't your competent? doctor have you eating oatmeal in the hospital years ago? NO? So, your doctor, hospital and board of directors are fuckingly incompetent? 

• Oatmeal (2 posts to May 2015)

Two Days of Oatmeal May Lower Bad Cholesterol by 10 Percent, Study Finds

Ketogenic Diet May Reduce Epileptic Seizures by Changing Brain Signals: Study

 

We've known of this problem a long time. Is this a guaranteed solution?

• 10% seizures post stroke (19 posts to April 2017)
• 5% epileptic seizures after stroke (10 posts to April 2021)

• epileptic seizures (6 posts to December 2015)

• post-stroke epilepsy (14 posts to December 2016) 

The latest here:

Ketogenic Diet May Reduce Epileptic Seizures by Changing Brain Signals: Study

Factor XIa Inhibition Drives Down Recurrent Stroke Risk Without Rise in Bleeding

 What is your doctor's EXACT PROTOCOL to prevent your next stroke?

Nothing?

But I guess your competent? doctor has known of asundexian for years already, RIGHT?

• Asundexian (5 posts to April 2025)

Factor XIa Inhibition Drives Down Recurrent Stroke Risk Without Rise in Bleeding

The investigational oral Factor XIa inhibitor asundexian has been shown to significantly reduce risk of repeat ischemic stroke without increasing bleeding risk in patients with recent noncardioembolic stroke. So reported investigators with the phase 3 OCEANIC-STROKE trial in a late-breaking science presentation at the International Stroke Conference 2026.

The relative risk reduction for recurrent stroke with asundexian was 26% when compared with placebo in the international study of more than 12,000 patients, all of whom also received standard antiplatelet therapy. The benefit was seen across a wide range of patient subgroups.

Stroke experts say the results represent a likely paradigm shift in secondary prevention of noncardioembolic ischemic events. “Up to now, we’ve been limited to antiplatelet medications like aspirin or clopidogrel for secondary stroke prevention in this setting,” says Andrew Russman, DO, Head of the Stroke Program at Cleveland Clinic and an OCEANIC-STROKE investigator. “But we’ve reached the limits of the stroke protection that can be achieved with antiplatelets, and we’re always concerned about increasing the risk of bleeding when we add other agents that act on the blood. What’s exciting about this study is that asundexian significantly lowered patients’ ischemic stroke risk without an increase in major bleeding risk. That’s an important advance.”

A pressing need for better secondary prevention

Secondary stroke prevention remains a primary concern for clinicians, as roughly one in four stroke survivors will face a subsequent stroke or stroke-like event. Despite the widespread use of antiplatelet regimens, the risk of recurrence remains substantial, often leading to more severe disability, higher mortality and a greater likelihood of post-stroke dementia.

Past efforts to improve these outcomes by adding traditional anticoagulants to antiplatelet therapy have been thwarted by bleeding concerns. While agents that inhibit Factor Xa or thrombin are effective at preventing clots, they also interfere with essential hemostasis, leading to unacceptably high rates of major bleeding. Inhibition of Factor XIa represents a biological breakthrough because the Factor XIa protein is essential for pathological thrombus growth but plays a negligible role in the normal physiological clotting required for healing.

“Factor XIa inhibitors represent an entirely new class of drugs that are relatively selective,” Dr. Russman explains. “That selectivity protects against harmful clots without impairing the clot formation that’s part of the body’s natural defense against excessive bleeding.”

OCEANIC-STROKE: Design at a glance

The OCEANIC-STROKE trial is one of the largest secondary prevention studies ever conducted, enrolling 12,327 patients across 702 international sites.

Participants were adults who had experienced a mild to moderate ischemic stroke (NIH Stroke Scale score ≤ 15) or a high-risk transient ischemic attack (TIA). Eligibility required that patients have noncardioembolic events, with exclusion of patients with atrial fibrillation, mechanical valves or other known cardiac sources of emboli.

Patients were randomized within 72 hours of index stroke onset to receive 50 mg of oral asundexian daily or a matching placebo. Randomization was done in a double-blind, parallel-group manner. Both groups continued their standard-of-care antiplatelet regimen, which was dual antiplatelet therapy for nearly 63% of the study population.

The trial was event-driven, with patients monitored for up to 31 months to assess the primary efficacy endpoint of recurrent ischemic stroke and the primary safety endpoint of major bleeding based on International Society on Thrombosis and Hemostasis criteria.

Results: Early and sustained efficacy with comparable bleeding rates

Mean patient age was 68 years, and two-thirds of patients were male. The index event was an ischemic stroke in 95% of participants and a high-risk TIA in 5%. The population was clinically diverse: 43% had large-artery atherosclerosis, 23% had small-vessel occlusion and 30% had strokes of undetermined etiology. Median drug exposure was 430 days.

The study met its primary goals with high levels of statistical significance. Among the key findings:

• Asundexian recipients had a 26% relative risk reduction, and a 2.2% absolute risk reduction, for recurrent ischemic stroke compared with placebo recipients (6.2% vs. 8.4%; hazard ratio [HR] = 0.74; 95% CI, 0.65-0.84). The divergence in event curves began early in the treatment course and was sustained throughout the study period.
• Despite the added antithrombotic effect, rates of major bleeding were nearly identical between the groups (1.9% with asundexian vs. 1.7% with placebo; HR = 1.10; 95% CI, 0.85-1.44).
• Asundexian was also associated with a significant reduction in disabling and fatal strokes (2.1% vs. 3.0%; HR = 0.69; 95% CI, 0.55-0.87).

The drug’s benefits were consistent across all analyzed subgroups, regardless of age, sex, stroke subtype, stroke risk factors, severity of index event, delivery of hyperacute treatment, geographic region and use of single or dual antiplatelet therapy.

“This suggests the benefits of FXIa inhibition are widely applicable to the varied presentations seen among noncardioembolic patients in a typical stroke center,” Dr. Russman notes.

Implications and next steps

The results of OCEANIC-STROKE suggest that FXIa inhibition could soon become a key component of secondary prevention in survivors of noncardioembolic stroke. “The ability to reduce the risk of ischemic stroke recurrence without an increase in bleeding is critically important for long-term management of these patients,” says Dr. Russman.

The investigators noted that the study is limited, however, by having a relatively small number of patients with severe stroke despite its broad inclusion criteria. Additional insights may emerge from ongoing monitoring of trial participants and from a substudy using standardized MRI to evaluate asundexian’s effect on subclinical clotting and micro-bleeding.

The agent has received FDA fast-track designation. If it receives approval, Dr. Russman says its exact role in practice won’t be clear until it sees wider clinical use. Additional assessment will be needed to address questions such as perioperative management and reversal in cases of bleeding emergencies.

He notes that studies of additional Factor XIa inhibitors are underway as well. “This class represents an exciting new era in secondary stroke prevention,” he concludes.

OCEANIC-STROKE was funded by Bayer, the commercial developer of asundexian.

Do GLP-1 drugs reduce inflammation?

What does your doctor think? Would they be useful in your recovery and prevention?

Do GLP-1 drugs reduce inflammation?

Q. In January 2025, you said that the new diabetes and weight-loss medications called GLP-1 drugs appeared to reduce the risk of many major diseases, by reducing inflammation. Do they still look so promising?

A. Even more so. In March 2025, a major new study was published in the journal Nature Medicine. The study involved nearly a million people with diabetes who took either GLP-1s or other diabetes medications and were followed for nearly a decade. Compared with those who didn’t take GLP-1s, those who did had a reduction of 10% to 20% in heart failure, cardiac arrest, lung failure, and pneumonia, and Alzheimer’s disease and other types of dementia. As with any drugs, some people experienced side effects, including stomach trouble, aching joints, and low blood pressure, but they were infrequent and relatively mild. Because these GLP-1s have been available for only a few years, we don’t yet know if long-term use will reveal additional adverse effects.

But this study and others linking medication with reduced inflammation continue to underline the importance of inflammation in several major diseases.

Nature Exposure Triggers Brain Reset

 Didn't your competent? doctor tell you about forest bathing AND had the therapist get you walking in nature? NO? So, ALL your stroke medical 'professionals' ARE COMPLETELY FUCKING INCOMPETENT?

• forest bathing (33 posts to September 2015)

Nature Exposure Triggers Brain Reset

Summary: Spending time in nature isn’t just a pleasant pastime; it triggers a measurable physiological and neurological “reset” in the brain. A comprehensive review of over 100 brain-imaging studies demonstrates that connecting with the natural world shifts brain activity toward restoration and relaxation.

By synthesizing decades of research, scientists identified a cascading pattern—from eased sensory processing to quieted mental rumination—that explains why even brief encounters with nature are so effective at combating stress and restoring attention.

Key Facts

• The Three-Minute Threshold: As little as three minutes in a natural environment can lead to measurable changes in brain activity, though longer immersion yields stronger, more lasting effects.
• Amygdala Deactivation: Nature exposure moves the body out of “fight-or-flight” mode, specifically reducing activity in the amygdala (the brain’s threat-detection center).
• Sensory Ease: Fractal patterns found in nature (like leaves or waves) are easier for the brain to process than the dense, fast-paced stimuli of urban or digital environments.
• Restorative Attention: Nature allows task-driven attention to rest, shifting the brain into a restorative mode where focus is gently guided by the environment.
• Quieting Rumination: Brain networks linked to repetitive, self-focused thinking become less active in nature, helping to settle “mental clutter.”

Source: McGill University

Spending time in nature, even briefly, triggers changes in the brain that calm stress, restore attention and quiet mental clutter, a new study has found.

Researchers at McGill University and colleagues at Adolfo Ibáñez University in Chile have examined more than 100 brain-imaging studies from various disciplines. The result is one of the most comprehensive reviews to date of how the brain responds to nature.

The findings add neuroscientific weight to the emerging field of nature connectedness, which seeks to better understand how humans relate to the natural world, an experience long recognized across cultures as central to well-being.

“We know intuitively that nature feels good, but neuroscience gives us a language that lends credibility to shaping decisions about how nature is considered in health policy and the spaces we build,” said co-lead author Mar Estarellas, a postdoctoral researcher in the Division of Social and Transcultural Psychiatry, Department of Psychiatry, McGill University.

Four signs of a more settled brain

By synthesizing results from a wide range of studies, the researchers identified what they call a cascading pattern in how the brain responds to nature:

• Shift in sensory processing: Fractal patterns in nature are easier for the brain to process and require less mental effort than the fast-paced and visually dense stimuli found in cities or online.
• Stress systems settle: As sensory load eases, the body shifts out of fight-or-flight mode. Heart rate slows, breathing deepens and brain regions involved in threat detection, such as the amygdala, show reduced activity.
• Attention restores itself: With stress reduced, the task-driven attention used in everyday life gives way to a more restorative mode of attention guided by the environment.
• Mental rumination quiets: Brain networks linked to repetitive self-focused thinking become less active, supporting a calmer sense of self.

What counts as ‘being in nature’?

Nature exposure exists along a spectrum, from time spent in parks or near water to full immersion in forests or waterfalls. It also extends to smaller encounters, such as keeping plants at home or looking at pictures of nature.

“As little as three minutes in a natural environment can lead to measurable changes, but more immersive, real-world experiences and longer exposure are generally associated with stronger and longer-lasting effects,” Estarellas said.

Nature as a mental reset

With concerns mounting about excessive screen time, Estarellas said the findings suggest nature offers a kind of mental reset that a digital detox alone can’t provide.

The evidence also supports movements toward green urban design and “social prescribing,” where doctors recommend time in nature.

“There’s also a broader societal impact,” said Estarellas. “Research shows people who feel more connected to nature tend to show more pro-environmental behaviour. Caring for nature and caring for ourselves aren’t separate, they reinforce each other.”

Funding: The study was supported by a grant from Mind & Life Institute.

Key Questions Answered:

Q: Is looking at a photo of a forest the same as being there?

A: Exposure exists on a spectrum. While looking at pictures or keeping houseplants can trigger minor positive changes, the study found that full, real-world immersion (like walking in a park or sitting by water) provides the most significant and long-lasting neurological benefits.

Q: Can “social prescribing” replace traditional therapy?

A: It’s an powerful tool in the kit. More doctors are now “prescribing” nature as a mental reset. The research shows that nature provides a specific kind of recovery from screen-induced fatigue that a simple digital detox cannot achieve on its own.

Q: Why does nature feel so much “easier” on the brain?

A: Because of fractals. Nature is filled with repeating, complex patterns that our brains are evolutionarily designed to process with minimal effort. Urban environments and screens, by contrast, are visually “loud” and force the brain into a constant state of high-alert processing.

Editorial Notes:

• This article was edited by a Neuroscience News editor.
• Journal paper reviewed in full.
• Additional context added by our staff.

About this neuroscience research news

Author: Aurelie Boucher
Source: McGill University
Contact: Aurelie Boucher – McGill University
Image: The image is credited to Neuroscience News

Original Research: Open access.
“Your brain on nature: A scoping review of the neuroscience of nature exposure” by Constanza Baquedano, Antonia Olguín, Luis Sebastian Contreras-Huerta, Fernando E. Rosas, and Mar Estarellas. Neuroscience & Biobehavioral Reviews
DOI:10.1016/j.neubiorev.2026.106565